Carolina Gallo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carolina Gallo has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Luis Serrano
Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology
4 shared publications - Maria Lluch-Senar
Pulmobiotics, Dr Aiguader 88, Barcelona, Spain
4 shared publications - Marc Weber
Flomics Biotech, SL, Carrer de Roc Boronat 31, 08005 Barcelona, Spain
3 shared publications - Raul Burgos
Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain
2 shared publications - Adrià Sogues
Structural and Molecular Microbiology, VIB-VUB Center for Structural Biology, VIB, Brussels, Belgium
1 shared publication - Bernhard Paetzold
S-Biomedic, Turnhoutseweg 30, 2340 Beerse, Belgium
1 shared publication
Latest Publications
- Open Access
- 29 August 2023
- Published by Springer Nature in Molecular Systems Biology
- Vol. 19 (10) , e11301
Comprehensive quantitative modeling of translation efficiency in a genome‐reduced bacterium
Translation efficiency has been mainly studied by ribosome profiling, which only provides an incomplete picture of translation kinetics. Here, we integrated the absolute quantifications of tRNAs, mRNAs, RNA half‐lives, proteins, and protein half‐lives with ribosome densities and derived the initiation and elongation rates for 475 genes (67% of all genes), 73 with high precision, in the bacterium Mycoplasma pneumoniae ( Mpn ). We found that, although the initiation rate varied over 160‐fold among genes, most of the known factors had little impact on translation efficiency. Local codon elongation rates could not be fully explained by the adaptation to tRNA abundances, which varied over 100‐fold among tRNA isoacceptors. We provide a comprehensive quantitative view of translation efficiency, which suggests the existence of unidentified mechanisms of translational regulation in Mpn .
- 29 August 2023
- Published by Springer Nature in Molecular Systems Biology
- Vol. 19 (10) , e11301
Open AccessComprehensive quantitative modeling of translation efficiency in a genome‐reduced bacterium
Translation efficiency has been mainly studied by ribosome profiling, which only provides an incomplete picture of translation kinetics. Here, we integrated the absolute quantifications of tRNAs, mRNAs, RNA half‐lives, proteins, and protein half‐lives with ribosome densities and derived the initiation and elongation rates for 475 genes (67% of all genes), 73 with high precision, in the bacterium Mycoplasma pneumoniae ( Mpn ). We found that, although the initiation rate varied over 160‐fold among genes, most of the known factors had little impact on translation efficiency. Local codon elongation rates could not be fully explained by the adaptation to tRNA abundances, which varied over 100‐fold among tRNA isoacceptors. We provide a comprehensive quantitative view of translation efficiency, which suggests the existence of unidentified mechanisms of translational regulation in Mpn .
- Open Access
Exploring the adaptability and robustness of the central carbon metabolism of Mycoplasma pneumoniae
In this study we explored the adaptability and robustness of glycolysis and pyruvate metabolism of Mycoplasma pneumoniae ( MPN ). We used a dual approach, we analysed metabolomics data collected for a large number of OE and KO mutants and perturbation samples. Furthermore, we trained a dynamic model of central carbon metabolism and tested the model’s capacity to predict these mutants and perturbation samples as well as identify key controlling factors in central carbon metabolism. Our analysis of metabolite data as well as our model analysis indicate MPN metabolism is inherently robust against perturbations due to its network structure. Two key control hubs of central carbon metabolism were identified.
Open AccessExploring the adaptability and robustness of the central carbon metabolism of Mycoplasma pneumoniae
In this study we explored the adaptability and robustness of glycolysis and pyruvate metabolism of Mycoplasma pneumoniae ( MPN ). We used a dual approach, we analysed metabolomics data collected for a large number of OE and KO mutants and perturbation samples. Furthermore, we trained a dynamic model of central carbon metabolism and tested the model’s capacity to predict these mutants and perturbation samples as well as identify key controlling factors in central carbon metabolism. Our analysis of metabolite data as well as our model analysis indicate MPN metabolism is inherently robust against perturbations due to its network structure. Two key control hubs of central carbon metabolism were identified.
- Open Access
- 1 October 2021
- Published by Springer Nature in Molecular Systems Biology
- Vol. 17 (10) , e10145
Engineering a genome‐reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo
Bacteria present a promising delivery system for treating human diseases. Here, we engineered the genome‐reduced human lung pathogen Mycoplasma pneumoniae as a live biotherapeutic to treat biofilm‐associated bacterial infections. This strain has a unique genetic code, which hinders gene transfer to most other bacterial genera, and it lacks a cell wall, which allows it to express proteins that target peptidoglycans of pathogenic bacteria. We first determined that removal of the pathogenic factors fully attenuated the chassis strain in vivo . We then designed synthetic promoters and identified an endogenous peptide signal sequence that, when fused to heterologous proteins, promotes efficient secretion. Based on this, we equipped the chassis strain with a genetic platform designed to secrete antibiofilm and bactericidal enzymes, resulting in a strain capable of dissolving Staphylococcus aureus biofilms preformed on catheters in vitro , ex vivo , and in vivo . To our knowledge, this is the first engineered genome‐reduced bacterium that can fight against clinically relevant biofilm‐associated bacterial infections.
- 1 October 2021
- Published by Springer Nature in Molecular Systems Biology
- Vol. 17 (10) , e10145
Open AccessEngineering a genome‐reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo
Bacteria present a promising delivery system for treating human diseases. Here, we engineered the genome‐reduced human lung pathogen Mycoplasma pneumoniae as a live biotherapeutic to treat biofilm‐associated bacterial infections. This strain has a unique genetic code, which hinders gene transfer to most other bacterial genera, and it lacks a cell wall, which allows it to express proteins that target peptidoglycans of pathogenic bacteria. We first determined that removal of the pathogenic factors fully attenuated the chassis strain in vivo . We then designed synthetic promoters and identified an endogenous peptide signal sequence that, when fused to heterologous proteins, promotes efficient secretion. Based on this, we equipped the chassis strain with a genetic platform designed to secrete antibiofilm and bactericidal enzymes, resulting in a strain capable of dissolving Staphylococcus aureus biofilms preformed on catheters in vitro , ex vivo , and in vivo . To our knowledge, this is the first engineered genome‐reduced bacterium that can fight against clinically relevant biofilm‐associated bacterial infections.
- Open Access
Widespread ribosome stalling in a genome-reduced bacterium and the need for translational quality control